Abstract Library

#4239 Implementation of a new, nurse-led clinic (NLC) for neuroendocrine tumor (NET) patients

Introduction: There is international evidence supporting nurse-led services for people with chronic diseases in reducing hospitalisations, symptom improvement and lifestyle, and patient satisfaction. Patients with NET often have high symptoms burden and psychosocial distress in the context of indolent disease. Our centre recently implemented a (NLC) to provide complex care support for patients with NET.

Conference:

Presenting Author:

Authors: Wakelin K, Michael M, Kong G, Rogers M, Natkunarajah N,

Keywords: Nurse-led care, Multidisciplinary care, Supportive care, Symptom management, Patient support,

#3648 Treatment preferences for somatostatin analogues in neuroendocrine tumors (NETs) among patients, clinicians and nurses in Australia

Introduction: Long-acting somatostatin analogues (LA SSAs) are commonly used as first-line treatment in low-grade pancreatic or midgut neuroendocrine tumors (NETs). Due to the long-term nature of treatment, treatment preferences should be taken into consideration. Funding for this study was provided by Ipsen.

Conference:

Presenting Author:

Authors: Cummins M, Fifer S, Winkler K, Cherian H,

Keywords: Treatment preferences, LA SSAs, NET,

#3500 HomeLAN: An international online survey to assess satisfaction with injection experience of patients with neuroendocrine tumors (NETs) enrolled in lanreotide autogel (LAN) Patient Support Programmes (PSPs)

Introduction: LAN is a long-term treatment for NETs, delivered in a ready-to-use syringe by monthly, deep subcutaneous injection. LAN PSPs aim to assist patients receiving their treatment at home, reducing both travel burden and the current risk of COVID-19 exposure. Furthermore, after training patients on stable dose can administer LAN independently (self or non-healthcare professional), where approved.

Conference:

Presenting Author: Hernando J

Authors: Hernando J, Kolarova T, Verslype C, Kaltsas G, Houchard A,

Keywords: neuroendocrine tumor, patient satisfaction, patient support programme, patient survey, lanreotide autogel,

#3276 Increasing compliance of an oral oncolytic through a novel clinical nurse educator model

Introduction: A patient education platform to help navigate medication coordination and symptom management leads to improved adherence and effective patient-HCP communication. Historically, cancer patients have lower rates of oral therapy adherence (~16%) versus patients receiving infusion therapy.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author:

Authors: Gaytan P, Weinman L, Early J, Ricardi D, Kifle B,

Keywords: adherence, clinical nurse educator, CNE, NSP, nurse support program, oral oncolytic,

#2078 Self-Reported Side Effects in Neuroendocrine Tumor (NET) Patients Prescribed Somatostatin Analogues – The Role for Specialist Dietitians and Nurses

Introduction: In practice, many patients with NETs report a change in symptoms after starting somatostatin analogues (SSA’s). Many health professionals and NET patient advocates have noticed that some of the side effects experienced by patients are more common than patient information literature suggests. It is therefore important to ask what and how severe experiences are, and compare to literature, to help raise awareness amongst NET health professionals.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Whyand T, Davies P, Bouvier C,

Keywords: B12, SSA, Side effects, Fat soluble vitamins,